These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6084435)

  • 1. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
    Giardina EG
    Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.
    Reidenberg MM; Drayer DE
    Angiology; 1986 Dec; 37(12 Pt 2):968-71. PubMed ID: 2433971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic interactions of procainamide and N-acetylprocainamide in isolated canine cardiac Purkinje fibers.
    Coyle JD; Carnes CA; Schaal SF; Muir WW
    J Cardiovasc Pharmacol; 1992 Aug; 20(2):197-205. PubMed ID: 1381010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.
    Sonnhag C; Karlsson E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits].
    Kusowska J
    Acta Pol Pharm; 1989; 46(1):90-7. PubMed ID: 2479226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
    Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ
    Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias.
    Sung RJ; Juma Z; Saksena S
    Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
    Winkle RA; Jaillon P; Kates RE; Peters F
    Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide.
    Singh BN; Feld G; Nademanee K
    Angiology; 1986 Dec; 37(12 Pt 2):930-8. PubMed ID: 2433967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow].
    Kusowska J; Polakowski P
    Acta Pol Pharm; 1989; 46(2):187-94. PubMed ID: 2483600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.